XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues [Abstract]        
Revenue $ 46,435 $ 37,919 $ 131,498 $ 124,492
Operating expenses        
Cost of revenue 16,667 19,346 54,035 55,937
Research and development 24,163 28,533 79,761 93,371
Sales and marketing 20,551 20,493 63,184 66,673
General and administrative 17,258 20,075 54,750 63,208
Amortization of intangible assets 428 428 1,275 1,270
Impairment of long-lived assets [1]     7,205  
Total operating expenses 79,067 88,875 260,210 280,459
Loss from operations (32,632) (50,956) (128,712) (155,967)
Interest and other income, net 3,474 4,282 11,462 10,918
Interest expense [2] (2,939) (3,652) (8,628) (10,788)
Net loss (32,097) (50,326) (125,878) (155,837)
Add: Net loss attributable to noncontrolling interest 26 26 78 28
Net loss attributable to Adaptive Biotechnologies Corporation $ (32,071) $ (50,300) $ (125,800) $ (155,809)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ (0.22) $ (0.35) $ (0.86) $ (1.08)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 147,516,398 144,704,868 146,908,234 144,208,940
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ (0.22) $ (0.35) $ (0.86) $ (1.08)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 147,516,398 144,704,868 146,908,234 144,208,940
[1] Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructurings for details on our restructuring expenses.
[2] Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.